[ad_1]
World pharma main Lupin Limited (Lupin) has introduced that it has acquired tentative approval from the USA Meals and Drug Administration (FDA) for its Abbreviated New Drug Software (ANDA), Drospirenone Tablets, 4 mg, to market a generic equal of Slynd Tablets, 4 mg, of Exeltis USA Inc.
Drospirenone Tablets (RLD Slynd) had estimated annual gross sales of USD 141 million within the U.S. (IQVIA MAT September 2022).
At round 1:31 PM, Lupin Ltd is at present buying and selling at Rs709.65 per share down by Rs2.5 or 0.35% from its earlier closing of Rs712.15 per share on the BSE.
[ad_2]
Source link